Ning Shao

US Patent:

8283360, Oct 9, 2012

Filed:

Dec 18, 2009

Appl. No.:

13/139656

Inventors:

Anandan Palani - Bridgewater NJ, US
Ashwin U. Rao - Avenel NJ, US
Xiao Chen - Edison NJ, US
Ning Shao - Clark NJ, US
Ying R. Huang - Berkeley Heights NJ, US
Robert G. Aslanian - Rockaway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/437
C07D 498/04

US Classification:

514301, 514302, 546114, 546115

Abstract:

The present invention relates to novel Bicyclic Heterocyclic Derivatives, pharmaceutical compositions comprising the Bicyclic Heterocyclic Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

US Patent:

8324213, Dec 4, 2012

Filed:

Oct 6, 2009

Appl. No.:

13/122679

Inventors:

Kevin D. McCormick - Basking Ridge NJ, US
Li Dong - Lawrenceville NJ, US
Christopher W. Boyce - Flemington NJ, US
Manuel de Lera Ruiz - Branchburg NJ, US
Salem Fevrier - Cranford NJ, US
Jie Wu - Scotch Plains NJ, US
Junying Zheng - New Providence NJ, US
Jianhua Chao - San Diego CA, US
Walter S. Won - Alpine NJ, US
Ashwin U. Rao - Avenel NJ, US
Rongze Kuang - Green Brook NJ, US
Pauline C. Ting - New Providence NJ, US
Xianhai Huang - Warren NJ, US
Ning Shao - Clark NJ, US
Anandan Palani - Bridgewater NJ, US
Michael Y. Berlin - Flemington NJ, US
Robert G. Aslanian - Rockaway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/501
A61K 31/497
A61K 31/506
A61K 31/4439
A61K 31/427
A61K 31/423
C07D 235/02
C07D 405/02
C07D 409/02
C07D 413/02
C07D 263/52

US Classification:

51425206, 51425505, 514256, 514278, 514365, 514375, 544230, 546 15, 548147, 548216, 548247

Abstract:

In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

US Patent:

8476274, Jul 2, 2013

Filed:

Oct 18, 2012

Appl. No.:

13/655176

Inventors:

Li Dong - Lawrenceville NJ, US
Christopher W. Boyce - Flemington NJ, US
Manuel de Lera Ruiz - Branchburg NJ, US
Salem Fevrier - Cranford NJ, US
Jie Wu - Scotch Plains NJ, US
Junying Zheng - New Providence NJ, US
Younong Yu - East Brunswick NJ, US
Jianhua Chao - San Diego CA, US
Walter S. Won - Alpine NJ, US
Ashwin U. Rao - Morganville NJ, US
Rongze Kuang - Green Brook NJ, US
Pauline C. Ting - New Providence NJ, US
Xianhai Huang - Warren NJ, US
Ning Shao - Clark NJ, US
Anandan Palani - Bridgewater NJ, US
Michael Y. Berlin - Flemington NJ, US
Robert G. Aslanian - Rockaway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/501
A61K 31/497
A61K 31/506
A61K 31/4439
A61K 31/427
A61K 31/423
C07D 235/02
C07D 405/02
C07D 409/02
C07D 413/02
C07D 263/52

US Classification:

51425206, 51425505, 514256, 514278, 514365, 514375, 544230, 546 15, 548147, 548216, 548247

Abstract:

In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

US Patent:

8569312, Oct 29, 2013

Filed:

Apr 4, 2013

Appl. No.:

13/857001

Inventors:

Li Dong - Lawrenceville NJ, US
Christopher W. Boyce - Flemington NJ, US
Manuel de Lera Ruiz - Branchburg NJ, US
Salem Fevrier - Cranford NJ, US
Jie Wu - Scotch Plains NJ, US
Junying Zheng - New Providence NJ, US
Younong Yu - East Brunswick NJ, US
Jianhua Chao - San Diego CA, US
Walter S. Won - Alpine NJ, US
Ashwin U. Rao - Morganville NJ, US
Rongze Kuang - Green Brook NJ, US
Pauline C. Ting - New Providence NJ, US
Xianhai Huang - Warren NJ, US
Ning Shao - Clark NJ, US
Anandan Palani - Bridgewater NJ, US
Michael Y. Berlin - Flemington NJ, US
Robert G. Aslanian - Rockaway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/506
A61K 31/501
A61K 31/4439
A61K 31/497
A61K 31/4184
C07D 235/02
C07D 405/10
C07D 409/10
C07D 403/10

US Classification:

514256, 51425206, 514278, 51425505, 514393, 514378, 544230, 546 15, 5483011, 548247, 5483007

Abstract:

In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

US Patent:

8592383, Nov 26, 2013

Filed:

Jun 14, 2012

Appl. No.:

13/523354

Inventors:

Xianhai Huang - Warren NJ, US
Jason Brubaker - Cambridge MA, US
Scott L. Peterson - Salem MA, US
John W. Butcher - Berlin MA, US
Joshua T. Close - Franklin MA, US
Michelle Martinez - Medford MA, US
Rachel Nicola MacCoss - Oxford, GB
Joon O. Jung - Newton MA, US
Phieng Siliphaivanh - Newton MA, US
Hongjun Zhang - Newton MA, US
Robert G. Aslanian - Rockaway NJ, US
Purakkattle Johny Biju - Piscataway NJ, US
Li Dong - Roselle Park NJ, US
Ying Huang - Berkeley Heights NJ, US
Kevin D. McCormick - Basking Ridge NJ, US
Anandan Palani - Bridgewater NJ, US
Ning Shao - Watchung NJ, US
Wei Zhou - Scotch Plains NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 221/16
C07D 401/10
C07D 413/10
A61K 31/473
A61K 31/501
A61K 31/506
A61K 31/5377
A61K 31/706
A61P 11/00
A61P 11/06
A61P 37/08
C07H 15/26

US Classification:

514 32, 51421018, 5142328, 51425204, 514256, 514290, 536 174, 544126, 544238, 544335, 546 79

Abstract:

The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I),.

US Patent:

20110207734, Aug 25, 2011

Filed:

Apr 14, 2011

Appl. No.:

13/086660

Inventors:

Anandan Palani - Bridgewater NJ, US
Dong Xiao - Warren NJ, US
Robert G. Aslanian - Rockaway NJ, US
Michael Y. Berlin - Flemington NJ, US
Ashwin U. Rao - Avenel NJ, US
Xiao Chen - Edison NJ, US
Yoon Joo Lee - Scotch Plains NJ, US
Sylvia Degrado - Scotch Plains NJ, US
Ning Shao - Clark NJ, US
Ying R. Huang - Berkeley Heights NJ, US
Zhidan Liu - Edison NJ, US

International Classification:

A61K 31/5377
C07D 401/12
A61K 31/4545
C07D 401/14
C07D 401/06
A61K 31/496
C07D 413/14
A61K 31/4725
C07D 417/14
A61K 31/506
A61P 11/00
A61P 37/08
A61P 11/02
A61P 29/00
A61P 9/00
A61P 1/00
A61P 25/00
A61P 3/00
A61P 3/04
A61P 3/10
A61P 3/08

US Classification:

5142358, 546194, 514318, 544360, 51425301, 544365, 51425313, 544121, 546148, 514307, 544316, 514274, 546187, 514316

Abstract:

The present invention relates to Azine Derivatives, pharmaceutical compositions comprising the Azine Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

US Patent:

20120122837, May 17, 2012

Filed:

Sep 23, 2011

Appl. No.:

13/242426

Inventors:

CLIFFORD CHENG - CAMBRIDGE MA, US
XIAOHUA HUANG - BROOKLINE MA, US
YING HUANG - BERKELEY HEIGHTS NJ, US
NING SHAO - WATCHUNG NJ, US
ASHWIN RAO - MORGANVILLE NJ, US
ANANDAN PALANI - BRIDGEWATER NJ, US
PETER ORTH - NEW YORK NY, US
JOHANNES H. VOIGT - CRANFORD NJ, US
ROBERT J. HERR - VOORHEESVILLE NY, US
LANA MICHELE ROSSITER - CLIFTON PARK NY, US
QI ZENG - DELMAR NY, US
XIANFENG SUN - GUILDERLAND NY, US

International Classification:

A61K 31/498
A61K 31/5377
A61K 31/4709
C07D 413/06
A61K 31/506
C07D 471/04
C07D 403/06
C07D 401/14
A61K 31/4985
C07D 403/14
C07D 241/44
A61P 3/04
A61P 3/10
A61P 9/10
A61P 3/06
A61K 31/55

US Classification:

51421018, 51421705, 5142348, 514249, 514312, 540599, 544116, 544295, 544350, 544354, 546157

Abstract:

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

US Patent:

20130079271, Mar 28, 2013

Filed:

Sep 22, 2010

Appl. No.:

13/499071

Inventors:

Kevin D. McCormick - Kenilworth NJ, US
Ning Shao - Kenilworth NJ, US
Younong Yu - Kenilworth NJ, US
Xianhai Huang - Kenilworth NJ, US
Manuel De Lera Ruiz - Kenilworth NJ, US
Anandan Palani - Kenilworth NJ, US
Junying Zheng - Kenilworth NJ, US
Christopher W. Boyce - Kenilworth NJ, US
Robert G. Aslanian - Kenilworth NJ, US
Jianhua Chao - San Diego CA, US

International Classification:

C07D 413/10
A61K 31/537
A61K 31/4245
A61K 38/02
A61K 31/423
A61K 31/4439
A61K 31/56
A61K 31/506
C07D 263/52

US Classification:

514 11, 544230, 514256, 544 71, 5142288, 548133, 514364, 548216, 514377, 546 15, 514278, 514171

Abstract:

In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.